S 5297 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
American Pharmaceutical Security Act
To require the Administrator of the Centers for Medicare & Medicaid Services to submit a report regarding the use of coverage and reimbursement authorities to protect the markets for active pharmaceutical ingredients and key staring materials.
Summary
- Requires the Administrator of the Centers for Medicare & Medicaid Services to submit a report to Congress within one year on using coverage and reimbursement authorities to protect U.S. markets for active pharmaceutical ingredients and key starting materials
- Directs the report to address strategies for reducing U.S. dependence on foreign adversaries for pharmaceutical ingredients and starting materials
- Directs the report to may include recommendations for price floor commitments to support domestic manufacturing of pharmaceutical ingredients and key starting materials against nonmarket practices and price manipulation
- Directs the report to may include recommendations to prioritize domestically manufactured pharmaceutical ingredients and key starting materials over foreign sources when domestic sources exist
- Directs the report to identify data and information gaps related to the origin and ownership of pharmaceutical ingredients and key starting materials that would be needed to implement the recommendations
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Sen. Schiff, Adam B. [D-CA] (D-CA)
1 cosponsor
- Sen. Scott, Rick [R-FL] (R-FL)
Actions (2)
- Aug 6, 2026 Read twice and referred to the Committee on Finance. · senate
- Aug 6, 2026 Introduced in Senate
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE SENATE OF THE UNITED STATES
August 6, 2026
Mr. Schiff (for himself and Mr. Scott of Florida) introduced the following bill; which was read twice and referred to the Committee on Finance
A BILL
To require the Administrator of the Centers for Medicare & Medicaid Services to submit a report regarding the use of coverage and reimbursement authorities to protect the markets for active pharmaceutical ingredients and key staring materials.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “American Pharmaceutical Security Act”.
SEC. 2. REPORT ON MARKETS FOR API AND KEY STARTING MATERIALS.
(a) In General.—Not later than 1 year after the date of enactment of this Act, the Administrator of the Centers for Medicare & Medicaid Services (referred to in this section as the “Administrator”) shall submit to Congress a report on its findings and policy recommendations regarding the use of coverage and reimbursement authorities to protect the markets of the United States and its allies for active pharmaceutical ingredients and key starting materials and reduce direct and indirect dependence on foreign adversaries (as described in section 791.4 of title 15, Code of Federal Regulations (or any successor regulations)) for such ingredients and materials.
(b) Contents.—The report under subsection (a)—
(1) may include—
(A) recommendations for price floor commitments in support of domestic manufacturing of active pharmaceutical ingredients and key starting materials to protect investments in the domestic markets of such ingredients and materials against nonmarket practices and price manipulation; and
(B) recommendations that would prioritize domestically manufactured active pharmaceutical ingredients and key starting materials over foreign manufactured active pharmaceutical ingredients and key starting materials when a domestic source for the applicable ingredient or material exists; and
(2) shall identify any existing gaps in data and information related to the origin and ownership of active pharmaceutical ingredients and key starting materials that the Administrator would need to implement the recommendations included in the report. <all>
Comments